Literature DB >> 3913530

Liposomes as targetable drug carriers.

V P Torchilin.   

Abstract

The general problem of targeted drug transport is critically reviewed and three principle components of targeted systems are discussed: the target, the vector molecule, and the carrier. Different systems of drug targeting are briefly described: local drug application, chemical modification of the drug molecule, physical targeting under the action of pH, temperature, or magnetic field. The idea of a vector molecule is discussed and different methods of vector molecule coupling with the drug are reviewed (direct coupling, coupling via spacer group or polymer molecule, etc.). It is shown that the most promising approach seems to be the use of a drug-containing microcontainer with the vector molecule immobilized on its outer surface. Different types of microcontainers are briefly described: microcapsules, cell hosts, and liposomes. The advantages of liposomes as drug containers are shown and the main problems of their use for drug targeting in vitro and in vivo conditions are discussed. One of the most important problems is the problem of vector molecule immobilization on liposome surfaces. The principle four different immobilization methods: adsorbtion, incorporation, covalent binding, and hydrophobic binding. Targeted liposome transport is described in model systems, cell cultures, and experimental animals. It is shown that targeted liposomes may release a drug via diffusion, lysis, or endocytosis by appropriate cells. The problems of targeted liposome technology and clinical application are analyzed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3913530

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  17 in total

Review 1.  Challenges in development of targeted liposomal therapeutics.

Authors:  Rupa R Sawant; Vladimir P Torchilin
Journal:  AAPS J       Date:  2012-03-14       Impact factor: 4.009

Review 2.  Integrating nanomedicine into clinical radiotherapy regimens.

Authors:  Allison N DuRoss; Megan J Neufeld; Shushan Rana; Charles R Thomas; Conroy Sun
Journal:  Adv Drug Deliv Rev       Date:  2019-07-04       Impact factor: 15.470

3.  Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).

Authors:  Brandon Smith; Ilya Lyakhov; Kristin Loomis; Danielle Needle; Ulrich Baxa; Amichai Yavlovich; Jacek Capala; Robert Blumenthal; Anu Puri
Journal:  J Control Release       Date:  2011-04-09       Impact factor: 9.776

Review 4.  The use of nanoparticulates to treat breast cancer.

Authors:  Xiaomeng Tang; Welley S Loc; Cheng Dong; Gail L Matters; Peter J Butler; Mark Kester; Craig Meyers; Yixing Jiang; James H Adair
Journal:  Nanomedicine (Lond)       Date:  2017-09-04       Impact factor: 5.307

Review 5.  Immunoconjugates and long circulating systems: origins, current state of the art and future directions.

Authors:  Alexander Koshkaryev; Rupa Sawant; Madhura Deshpande; Vladimir Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2012-09-03       Impact factor: 15.470

6.  Doxorubicin loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumor.

Authors:  Dongin Kim; Eun Seong Lee; Kyeongsoon Park; Ick Chan Kwon; You Han Bae
Journal:  Pharm Res       Date:  2008-05-01       Impact factor: 4.200

7.  Synthetic trehalose glycolipids confer desiccation resistance to supported lipid monolayers.

Authors:  Christopher W Harland; Zsofia Botyanszki; David Rabuka; Carolyn R Bertozzi; Raghuveer Parthasarathy
Journal:  Langmuir       Date:  2009-05-05       Impact factor: 3.882

8.  HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents.

Authors:  Anu Puri; Gabriela Kramer-Marek; Ryan Campbell-Massa; Amichai Yavlovich; Shrikant C Tele; Sang-Bong Lee; Jeffrey D Clogston; Anil K Patri; Robert Blumenthal; Jacek Capala
Journal:  J Liposome Res       Date:  2008       Impact factor: 3.648

Review 9.  Targeted pharmaceutical nanocarriers for cancer therapy and imaging.

Authors:  Vladimir P Torchilin
Journal:  AAPS J       Date:  2007-05-11       Impact factor: 4.009

10.  PEG length and chemical linkage controls polyacridine peptide DNA polyplex pharmacokinetics, biodistribution, metabolic stability and in vivo gene expression.

Authors:  Sanjib Khargharia; Koby Kizzire; Mark D Ericson; Nicholas J Baumhover; Kevin G Rice
Journal:  J Control Release       Date:  2013-06-02       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.